FDA Explains How Generic Firms Will Self-Identify Facilities Under New User Fee Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidance on meeting the new self-identification requirement is one of several GDUFA-related announcements issued by FDA Aug. 22. The agency will hold a public meeting Sept. 21 to solicit comments on user fee program implementation issues.
You may also be interested in...
GDUFA Facility Self-Identification Pace Slow As Deadline Neared
API, finished dosage form and other facilities in the generic drug supply chain must submit information to FDA by Dec. 3. As of Nov. 18, about one-third had complied, potentially affecting user fee amounts.
Generic Drug User Fees Lower Than Expected, Thanks To Higher Volume
Fiscal year 2013 fees for new ANDAs, prior approval supplements, backlogged applications and drug master files are 3%-50% below the agency’s initial projections.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.